

Paulus Kirchhof

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3296251/paulus-kirchhof-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512
papers

114,380
citations

102
h-index

337
g-index

646
ext. papers

137,641
ext. citations

6.2
avg, IF

7.41
L-index

#	Paper	IF	Citations
512	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
511	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2016 , 18, 891-975	12.3	4036
510	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
509	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). <i>European Heart Journal</i> , 2016 , 37, 2313-2331	9.5	3919
508	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2015 , 36, 2611-2654	9.5	3850
507	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1771-847	9.5	3691
506	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2014 , 35, 2541-2619	9.5	3467
505	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>European Respiratory Journal</i> , 2015 , 46, 3093-3232	9.5	3455
504	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
503	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
502	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363
501	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2013 , 34, 2949-3003	9.5	3076
500	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012 , 33, 2451-96	9.5	2866
499	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	9.5	2797
498	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
497	2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>European Heart Journal</i> , 2015 , 36, 3075-3128	9.5	2465
496	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2733-79	9.5	2361

495	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2873-926	9.5	2334
494	Third universal definition of myocardial infarction. <i>Circulation</i> , 2012 , 126, 2020-35	16.7	2259
493	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology	9.5	2187
492	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
491	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2551-67	9.5	2064
490	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
489	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
488	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999-3058	17.81	3058
487	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)	9.5	1676
486	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2013 , 34, 2281-2306	9.5	1491
485	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013 , 34, 3035-87	9.5	1444
484	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in	6.7	1314
483	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
482	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 2716-2801	9.5	1249
481	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. <i>Europace</i> , 2012 , 14, 528-606	3.9	1160
480	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Europace</i> , 2010 , 12, 1360-420	3.9	1120
479	2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2015 , 36, 2921-2964	9.5	1102
478	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1385-413	3.9	1019

477	Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardio-thoracic Surgery</i> , 2012 , <i>42</i> , 51-144	3	1002
476	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , <i>35</i> , 2383-431	9.5	849
475	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , <i>17</i> , 1467-507	3.9	803
474	Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. <i>Physiological Reviews</i> , 2011 , <i>91</i> , 265-325	47.9	785
473	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013 , <i>15</i> , 625-51	3.9	622
472	Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2005 , <i>26</i> , 2422-34	9.5	613
471	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , <i>50</i> , e1-e88	3	589
470	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Journal of Cardio-thoracic Surgery</i> , 2014 , <i>46</i> , 1-114	3	588
469	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014 , <i>23</i> , 3-16	1.7	474
468	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association of Preventive Cardiology (EAPC). <i>European Heart Journal</i> , 2016 , <i>37</i> , 2313-2331	3.9	445
467	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by Association for European Pediatric and Congenital Cardiology (AEPCC). <i>Europace</i> , 2015 , <i>17</i> , 1601-87	3.9	426
466	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Cardiovascular Interventional and Electrophysiological Physicians (EAPCI). <i>European Heart Journal</i> , 2015 , <i>36</i> , 1711-1747	9.5	413
465	Ca ²⁺ /calmodulin-dependent protein kinase II regulates cardiac Na ⁺ channels. <i>Journal of Clinical Investigation</i> , 2006 , <i>116</i> , 3127-38	15.9	397
464	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. <i>Europace</i> , 2013 , <i>15</i> , 1389-406	3.9	379
463	Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. <i>JAMA Cardiology</i> , 2020 , <i>5</i> , 1281-1285	16.2	371
462	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020 , <i>383</i> , 1305-1316	59.2	337
461	Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. <i>Lancet, The</i> , 2014 , <i>384</i> , 2235-43	4.0	323
460	Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. <i>Circulation</i> , 2006 , <i>114</i> , 1799-806	16.7	321

459	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1145-53	9.5	319
458	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
457	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2013 , 22, 193-278	28.7	286
456	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events--European Registry in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , 2014 , 16, 6-14	3.9	283
455	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013 , 34, 2094-106	9.5	281
454	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 3346-55	9.5	278
453	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018 , 50, 1225-1233	36.3	277
452	Outcome parameters for trials in atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2007 , 28, 2803-17	9.5	267
451	The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. <i>Europace</i> , 2009 , 11, 423-34	3.9	263
450	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012 , 33, 171-257	2.4	250
449	Indications for the use of diagnostic implantable and external ECG loop recorders. <i>Europace</i> , 2009 , 11, 671-87	3.9	238
448	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 13-28	7	232
447	Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. <i>European Heart Journal</i> , 2008 , 29, 2125-32	9.5	229
446	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014 , 16, 308-19	3.9	224
445	PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 123-33		207
444	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014 , 35, 2001-9	9.5	199
443	Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007 , 9, 1006-23	3.9	197
442	Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 218-25	4.7	195

441	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , <i>19</i> , 9-12	12.3	189
440	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , <i>105</i> , 997-1011	7	184
439	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Heart Rhythm</i> , 2014 , <i>11</i> , e166-96	6.7	179
438	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular	9.5	179
437	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , <i>351</i> , h4451	5.9	172
436	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011 , <i>13</i> , 723-46	3.9	166
435	Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. <i>Lancet, The</i> , 2002 , <i>360</i> , 1275-9	4.0	164
434	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017 , <i>38</i> , 2137-2149	9.5	162
433	Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). <i>European Heart Journal</i> , 2014 , <i>35</i> , 3365-76	9.5	161
432	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012 , <i>14</i> , 8-27	3.9	156
431	Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. <i>Stroke</i> , 2012 , <i>43</i> , 2689-94	6.7	154
430	Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. <i>Stroke</i> , 2013 , <i>44</i> , 3357-64	6.7	152
429	Introducing the German Mouse Clinic: open access platform for standardized phenotyping. <i>Nature Methods</i> , 2005 , <i>2</i> , 403-4	21.6	148
428	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017 , <i>190</i> , 12-18	4.9	143
427	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Española De Cardiología</i> , 2016 , <i>69</i> , 177.e1-177.e62	1.5	137
426	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. <i>European Heart Journal</i> , 2009 , <i>30</i> , 2969-77c	9.5	136
425	Brugada syndrome and supraventricular tachyarrhythmias: a novel association?. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , <i>12</i> , 680-5	2.7	136
424	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Europace</i> , 2014 , <i>16</i> , 1257-83	3.9	135

423	EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. <i>Europace</i> , 2010 , 12, 1480-9	3.9	135
422	The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. <i>European Heart Journal</i> , 2003 , 24, 1104-12	9.5	135
421	Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca ²⁺ -dependent action potential remodeling. <i>Circulation Research</i> , 2003 , 92, 428-36	15.7	130
420	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014 , 35, 1448-56	9.5	128
419	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 50	0.7	124
418	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). <i>Europace</i> , 2012 , 14, 278-93	3.9	124
417	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHS). <i>Europace</i> , 2015 , 17, 1197-214	3.9	123
416	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018 , 39, 2942-2955	9.5	121
415	Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 43-51	6.4	121
414	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016 , 203, 660-6	3.2	116
413	Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. <i>Lancet, The</i> , 2012 , 380, 238-46	4.0	113
412	Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 1027-33	2.7	104
411	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>American Heart Journal</i> , 2013 , 166, 442-8	4.9	102
410	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013 , 15, 1540-56	3.9	101
409	Ca/calmodulin kinase II differentially modulates potassium currents. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009 , 2, 285-94	6.4	98
408	Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. <i>Europace</i> , 2008 , 10, 21-7	3.9	98
407	Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1119-30	15.9	98
406	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. <i>European Heart Journal</i> , 2018 , 39, 2959-2971	9.5	97

405	Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. <i>Nature Reviews Cardiology</i> , 2016 , 13, 230-248	14.8	97
404	G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 87-97	16.6	95
403	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-european egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , 2017 , 6,	6	93
402	Survivin determines cardiac function by controlling total cardiomyocyte number. <i>Circulation</i> , 2008 , 117, 1583-93	16.7	93
401	Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2019 , 140, 1834-1850	16.7	93
400	Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. <i>EMBO Journal</i> , 2008 , 27, 692-703	13	91
399	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 1167.e1-1167.e85	1.5	91
398	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016 , 18, 37-50	3.9	90
397	Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 143-9	15.1	89
396	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. <i>Europace</i> , 2014 , 16, 965-72	3.9	88
395	Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 740-50	15.1	86
394	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009 , 11, 860-85	3.9	84
393	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. <i>Circulation</i> , 2020 , 142, 2095-2106	16.7	83
392	Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. <i>Circulation</i> , 1998 , 97, 2567-74	16.7	82
391	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet, The</i> , 2017 , 390, 1873-1887	40	81
390	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014 , 16, 1655-73	3.9	77
389	Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 833-41	7	77
388	Management of patients with palpitations: a position paper from the European Heart Rhythm Association. <i>Europace</i> , 2011 , 13, 920-34	3.9	77

387	Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?. <i>Herz</i> , 2005 , 30, 91-101	2.6	77
386	One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. <i>Clinical Cardiology</i> , 2014 , 37, 357-64	3.3	76
385	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017 , 38, 20-26	9.5	75
384	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
383	Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. <i>Clinical Research in Cardiology</i> , 2011 , 100, 897-905	6.1	73
382	Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. <i>Cardiovascular Research</i> , 2003 , 59, 390-9	9.9	72
381	Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. <i>Journal of Clinical Investigation</i> , 2010 , 120, 617-26	15.9	71
380	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. <i>Europace</i> , 2018 , 20, 225-233	3.9	70
379	Detection of asymptomatic cerebral microbleeds: a comparative study at 1.5 and 3.0 T. <i>Academic Radiology</i> , 2008 , 15, 895-900	4.3	67
378	Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. <i>Cardiovascular Research</i> , 2003 , 57, 1085-93	9.9	67
377	Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. <i>Basic Research in Cardiology</i> , 2003 , 98, 25-32	11.8	67
376	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 1268-1276	9.5	67
375	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1024-1030	5.1	66
374	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018 , 20, 395-407	3.9	66
373	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014 , 35, 3250-7	9.5	66
372	Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. <i>European Heart Journal</i> , 2002 , 23, 1394-401	9.5	66
371	Venice Chart international consensus document on atrial fibrillation ablation: 2011 update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 890-923	2.7	65
370	Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation. <i>Stem Cells</i> , 2015 , 33, 1456-69	5.8	64

369	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. <i>Cardiovascular Research</i> , 2011 , 92, 67-74	9.9	64
368	Myocardial vulnerability to T wave shocks: relation to shock strength, shock coupling interval, and dispersion of ventricular repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 1996 , 7, 231-42	2.7	63
367	Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016 , 353, i1855	5.9	62
366	A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). <i>European Heart Journal</i> , 2005 , 26, 1292-7	9.5	62
365	Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. <i>Journal of Biological Chemistry</i> , 2005 , 280, 6906-14	5.4	62
364	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. <i>Nature Reviews Cardiology</i> , 2017 , 14, 701-714	14.8	61
363	Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. <i>Europace</i> , 2014 , 16, 787-96	3.9	61
362	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1012-9	7	60
361	Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. <i>PLoS ONE</i> , 2011 , 6, e26389	3.7	60
360	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013 , 34, 1869-74	9.5	59
359	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017 , 19, 169-179	3.9	58
358	Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 1010-23	7	56
357	Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 401-7	2.7	56
356	An introduction to murine models of atrial fibrillation. <i>Frontiers in Physiology</i> , 2012 , 3, 296	4.6	52
355	Left atrial catheter ablation and ischemic stroke. <i>Stroke</i> , 2012 , 43, 265-70	6.7	52
354	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. <i>European Heart Journal</i> , 2016 , 37, 1881-1894	9.5	51
353	PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1881-1894	15.1	50
352	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50

351	Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. <i>Europace</i> , 2009 , 11, 1362-8	3.9	50
350	Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2002 , 13, 742-9	2.7	50
349	Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2004 , 36, 691-700	5.8	49
348	Wolff-Parkinson-White syndrome associated with Brugada syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 1423-4	1.6	49
347	Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 257-63	4.7	48
346	Routine data from hospital information systems can support patient recruitment for clinical studies. <i>Clinical Trials</i> , 2010 , 7, 183-9	2.2	47
345	Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. <i>Cardiovascular Research</i> , 2010 , 87, 60-72	9.9	47
344	Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 285, H145-53	5.2	47
343	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 747-54	9.5	46
342	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 409-419	15.1	46
341	Expert opinion paper on atrial fibrillation detection after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2018 , 107, 871-880	6.1	45
340	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016 , 203, 22-9	3.2	45
339	Prevalence of unknown atrial fibrillation in patients with risk factors. <i>Europace</i> , 2013 , 15, 657-62	3.9	45
338	Endocardial mapping of right ventricular outflow tract tachycardia using noncontact activation mapping. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 602-8	2.7	45
337	Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. <i>Europace</i> , 2009 , 11, 1338-44	3.9	43
336	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. <i>Heart Rhythm</i> , 2010 , 7, 1862-9	6.7	42
335	Electro-anatomic mapping systems in arrhythmias. <i>Europace</i> , 2008 , 10 Suppl 3, iii28-34	3.9	42
334	Computer analysis of monophasic action potentials: manual validation and clinically pertinent applications. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 1666-78	1.6	42

333	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. <i>Europace</i> , 2011 , 13, 1517-25	3.9	41
332	Effects of thoracic epidural anesthesia with and without autonomic nervous system blockade on cardiac monophasic action potentials and effective refractoriness in awake dogs. <i>Anesthesiology</i> , 2001 , 95, 132-8; discussion 6A	4.3	41
331	Electrocardiographic risk stratification in families with congenital long QT syndrome. <i>European Heart Journal</i> , 2006 , 27, 2074-80	9.5	40
330	New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. <i>Europace</i> , 2014 , 16, 1093-28	3.9	39
329	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012 , 164, 292-302.e1	4.9	39
328	Ivabradine in patients with inappropriate sinus tachycardia. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 382, 483-6	3.4	39
327	Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice. <i>International Journal of Cardiology</i> , 2013 , 166, 366-74	3.2	38
326	Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. <i>Europace</i> , 2014 , 16, 812-9	3.9	37
325	Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. <i>Cardiovascular Research</i> , 2004 , 62, 500-8	9.9	36
324	Insights into sick sinus syndrome from an inducible mouse model. <i>Cardiovascular Research</i> , 2011 , 90, 38-48	9.9	35
323	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 141-153	15.1	35
322	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
321	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019 , 132, 749-757.e5	2.4	34
320	ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology. <i>Scientific Reports</i> , 2019 , 9, 1389	4.9	33
319	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	33
318	A novel nonfluoroscopic catheter visualization system (LocaLisa) to reduce radiation exposure during catheter ablation of supraventricular tachycardias. <i>American Journal of Cardiology</i> , 2002 , 90, 340-3	3.8	33
317	PITX2-dependent gene regulation in atrial fibrillation and rhythm control. <i>Journal of Physiology</i> , 2017 , 595, 4019-4026	3.9	32
316	Load-induced changes in repolarization: evidence from experimental and clinical data. <i>Basic Research in Cardiology</i> , 2001 , 96, 369-80	11.8	32

315	Proarrhythmia in a non-failing murine model of cardiac-specific Na ⁺ /Ca ²⁺ exchanger overexpression: whole heart and cellular mechanisms. <i>Basic Research in Cardiology</i> , 2012 , 107, 247	11.8	31
314	Modification of stretch-induced shortening of repolarization by streptomycin in the isolated rabbit heart. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, 711-21	3.1	31
313	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 176	0.7	30
312	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019 , 9, e022478	3	29
311	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017 , 7, e015099	3	29
310	Cardiac overexpression of the human 5-HT ₄ receptor in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H788-98	5.2	29
309	Regional, age-dependent, and genotype-dependent differences in ventricular action potential duration and activation time in 410 Langendorff-perfused mouse hearts. <i>Basic Research in Cardiology</i> , 2009 , 104, 523-33	11.8	29
308	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <i>American Heart Journal</i> , 2016 , 179, 59-68	4.9	29
307	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 3793-3799c	9.5	29
306	Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis--data from the German Competence Network on Atrial Fibrillation. <i>Europace</i> , 2015 , 17, 1354-62	3.9	28
305	Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. <i>Cardiovascular Research</i> , 2012 , 95, 317-26	9.9	28
304	Fetoscopic transesophageal electrocardiography and stimulation in fetal sheep: a minimally invasive approach aimed at diagnosis and termination of therapy-refractory supraventricular tachycardias in human fetuses. <i>Circulation</i> , 1999 , 100, 772-6	16.7	28
303	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018 , 197, 124-132	4.9	27
302	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. <i>Clinical Cardiology</i> , 2016 , 39, 565-569	3.3	27
301	'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 2853	9.5	27
300	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VerT trial. <i>Europace</i> , 2016 , 18, 184-90	3.9	27
299	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 938.e1-938.e59	1.5	27
298	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. <i>Europace</i> , 2011 , 13, 1166-73	3.9	27

297	A patient with "atrial torsades de pointes". <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 806-11	2.7	27
296	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018 , 265, 141-147	3.2	26
295	Reduced arrhythmogenicity of biphasic versus monophasic T-wave shocks. Implications for defibrillation efficacy. <i>Circulation</i> , 1996 , 94, 1974-80	16.7	26
294	Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. <i>Heart</i> , 2014 , 100, 1408-13	5.1	25
293	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>EuroIntervention</i> , 2015 , 10, 1095-108	3.1	25
292	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. <i>Europace</i> , 2017 , 19, 132-138	3.9	24
291	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. <i>Europace</i> , 2019 , 21, 1459-1467	3.9	24
290	Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 106, 263-8	3.1	24
289	Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. <i>Europace</i> , 2009 , 11, 42-7	3.9	24
288	Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. <i>Journal of Cardiovascular Electrophysiology</i> , 2004 , 15, 1310-6	2.7	24
287	Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. <i>American Heart Journal</i> , 2016 , 172, 19-25	4.9	23
286	Cardiac Optogenetics and Optical Mapping - Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology. <i>Frontiers in Physiology</i> , 2019 , 10, 182	4.6	23
285	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014 , 10, 425-34	4.4	23
284	Semi-automated 3-dimensional intracardiac echocardiography: development and initial clinical experience of a new system to guide ablation procedures. <i>Heart Rhythm</i> , 2006 , 3, 1453-9	6.7	23
283	Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 287, H2216-25	5.2	23
282	Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. <i>Basic Research in Cardiology</i> , 2005 , 100, 112-21	11.8	23
281	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016 , 2, 299-305	4.6	23
280	Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation. <i>Circulation Research</i> , 2020 , 127, 34-50	15.7	22

279	Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.	4.9	22
278	Tachycardia detection performance of implantable loop recorders: results from a large 'real-life' patient cohort and patients with induced ventricular arrhythmias. <i>Europace</i> , 2013 , 15, 1215-22	3.9	22
277	What are the costs of atrial fibrillation?. <i>Europace</i> , 2011 , 13 Suppl 2, ii9-12	3.9	22
276	Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H1539-46	5.2	22
275	Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. <i>BMJ Open</i> , 2018 , 8, e022690	3	22
274	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). <i>Annals of Noninvasive Electrocardiology</i> , 2012 , 17, 36-56	1.5	21
273	Primary prevention of sudden cardiac death. <i>Heart</i> , 2006 , 92, 1873-8	5.1	21
272	A Regional Reduction in Ito and IKACH in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity. <i>PLoS ONE</i> , 2016 , 11, e0154077	3.7	21
271	Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. <i>Neurology</i> , 2019 , 92, e115-e124	6.5	21
270	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. <i>Europace</i> , 2020 , 22, 748-760	3.9	20
269	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014 , 100, 1625-35	5.1	20
268	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <i>Netherlands Heart Journal</i> , 2017 , 25, 551-558	2.2	20
267	Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination. <i>Genesis</i> , 2004 , 39, 288-98	1.9	20
266	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 70-79	6.4	20
265	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. <i>Europace</i> , 2020 , 22, 1149-1161	3.9	19
264	Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Circulation Journal</i> , 2014 , 78, 2674-81	2.9	19
263	The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>European Heart Journal</i> , 2015 , 36, 255-6	9.5	19
262	Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. <i>Kidney International</i> , 2015 , 87, 200-9	9.9	19

261	Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. <i>Clinical Cardiology</i> , 2014 , 37, 277-84	3.3	19
260	Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. <i>Progress in Biophysics and Molecular Biology</i> , 2012 , 110, 340-6	4.7	19
259	Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 962-71	5.8	19
258	Transient local changes in right ventricular monophasic action potentials due to ajmaline in a patient with Brugada Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 1010-5	2.7	19
257	Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. <i>Europace</i> , 2018 , 20, 1612-1620	3.9	17
256	Flecainide acetate for the treatment of atrial and ventricular arrhythmias. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 347-57	4	17
255	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, E864-70	2.7	17
254	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 53.e1-53.e46	1.5	17
253	An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. <i>Progress in Biophysics and Molecular Biology</i> , 2014 , 115, 340-8	4.7	17
252	Shock-induced dispersion of ventricular repolarization: implications for the induction of ventricular fibrillation and the upper limit of vulnerability. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 998-1008	2.7	17
251	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry. <i>BMC Neurology</i> , 2015 , 15, 129	3.1	16
250	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 165	2.3	16
249	Approach to wide complex tachycardias in patients without structural heart disease. <i>Heart</i> , 2006 , 92, 704-11	5.1	16
248	Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial. <i>American Heart Journal</i> , 2005 , 150, 899	4.9	16
247	Gender differences in cardiac arrhythmias. <i>Herz</i> , 2005 , 30, 390-400	2.6	16
246	Clinical aspects of ventricular arrhythmias associated with QT prolongation. <i>European Heart Journal Supplements</i> , 2001 , 3, K81-K88	1.5	16
245	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for	9.5	15
244	T-wave alternans does not assess arrhythmic risk in patients with Brugada syndrome. <i>Annals of Noninvasive Electrocardiology</i> , 2004 , 9, 162-5 <i>Journal</i> , 2012 , 33, 2126-2126	1.5	15

243	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. <i>International Journal of Cardiology</i> , 2018 , 270, 160-166	3.2	15
242	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 74-84	2.7	14
241	Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK. <i>BMJ Open</i> , 2015 , 5, e009267	3	14
240	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study. <i>International Journal of Cardiology</i> , 2015 , 183, 105-10	3.2	14
239	Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. <i>Evidence-Based Medicine</i> , 2014 , 19, 222-3		14
238	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021 , 23, 329-344	3.9	14
237	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021 , 144, 845-858	16.7	14
236	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017 , 232, 98-104	3.2	13
235	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española De Cardiología</i> , 2013 , 66, 880.e1-880.e64	1.5	13
234	Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial. <i>International Journal of Cardiology</i> , 2013 , 168, 3977-81	3.2	13
233	Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. <i>Lancet Neurology</i> , 2021 , 20, 426-436	24.1	13
232	Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 97-104	1.9	13
231	Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 157-162	6.4	12
230	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. <i>Europace</i> , 2020 , 22, 1026-1035	3.9	12
229	Phenotyping of Mice with Heart Specific Overexpression of A-Adenosine Receptors: Evidence for Cardioprotective Effects of A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2018 , 9, 13	5.6	12
228	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014 , 4, e004700	3	12
227	Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2012 , 23, 186-95	0.8	12
226	Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG). <i>Clinical Research in Cardiology</i> , 2010 , 99, 609-25	6.1	12

225	Phase angle convergence of multiple monophasic action potential recordings precedes spontaneous termination of ventricular fibrillation. <i>Basic Research in Cardiology</i> , 1998 , 93, 412-21	11.8	12
224	Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. <i>JCI Insight</i> , 2020 , 5,	9.9	12
223	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020 , 41, 3605-3692	9.5	12
222	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 604-612	4.3	12
221	Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern. <i>Kardiologe</i> , 2017 , 11, 193-204	0.6	11
220	Clinical Potential of Targeting Fibroblast Growth Factor-23 and Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020 , 9, e016041	6	11
219	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. <i>Cardiovascular Research</i> , 2018 , 114, 1313-1323	9.9	11
218	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018 , 20, e87-e95	3.9	11
217	Guía ESC 2015 sobre el tratamiento de pacientes con arritmias ventriculares y prevención de la muerte súbita cardíaca. <i>Revista Española De Cardiología</i> , 2016 , 69, 176.e1-176.e77	1.5	11
216	2012 focused update of the ESC Guidelines for the management of atrial fibrillation [Eur Heart J (2012); 33(21):2719-2747]. <i>European Heart Journal</i> , 2013 , 34, 790-790	9.5	11
215	Outcome of left atrial appendage occlusion in high-risk patients. <i>Heart</i> , 2018 , 104, 594-599	5.1	11
214	Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 317, C1256-C1267	5.4	10
213	Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. <i>Journal of the American Heart Association</i> , 2020 , 9, e009530	6	10
212	Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg. <i>Clinical Research in Cardiology</i> , 2018 , 107, 193-200	6.1	10
211	Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. <i>Heart</i> , 2018 , 104, 1608-1614	5.1	10
210	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012: Actualización de las guías de la Sociedad Europea de Cardiología (ESC) para el manejo de la fibrilación auricular de 2010 Elaborada en colaboración con la Asociación Europea del Ritmo Cardíaco. <i>Revista Española De Cardiología</i> , 2013 , 66, 54.e1-54.e24	1.5	10
209	Incessant supraventricular tachycardia with constant 1:2 atrioventricular ratio: a longitudinally dissociated atrioventricular node?. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 316-9	2.7	10
208	Prolonged QRS duration increases QT dispersion but does not relate to arrhythmias in survivors of acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 789-95	1.6	10

207	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e012241	3	10
206	Guñ ESC 2016 sobre prevenciñ de la enfermedad cardiovascular en la prñtica clñica. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 939.e1-939.e87	1.5	10
205	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f30-f39	6.4	10
204	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2058	0.8	10
203	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2021 ,	9.5	10
202	Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VerT Trial. <i>TH Open</i> , 2020 , 4, e20-e32	2.7	9
201	Evidence for Arrhythmogenic Effects of A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1051	5.6	9
200	Guñ de Prñtica Clñica de la ESC 2013 sobre diagnñtico y tratamiento de la cardiopatñ isquñica estable. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 135.e1-135.e81	1.5	9
199	Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice. <i>Naunyn-Schmiedebergs Archives of Pharmacology</i> , 2013 , 386, 227-38	3.4	9
198	Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. <i>Europace</i> , 2008 , 10, 433-7	3.9	9
197	New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2007 , 4, 790-3	6.7	9
196	Hypertension begets hypertrophy begets atrial fibrillation? Insights from yet another sheep model. <i>European Heart Journal</i> , 2006 , 27, 2919-20	9.5	9
195	Torsade de pointes induced by ajmaline. <i>Clinical Research in Cardiology</i> , 2001 , 90, 586-90		9
194	Clinical value of electrocardiographic parameters in genotyped individuals with familial long QT syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 406-15	1.6	9
193	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 1295-1303	3.7	9
192	Positionspapier zur Detektion von Vorhofflimmern nach ischñischem Schlaganfall. <i>Aktuelle Neurologie</i> , 2018 , 45, 93-106		9
191	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1984-1986	15.1	9
190	Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	9

189	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019 , 42, 1147-1154	3.3	8
188	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 386	4.3	8
187	Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2019 , 124, 465-475	3	8
186	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Española De Cardiología</i> , 2014 , 67, 136.e1-136.e56	1.5	8
185	Kommentar zu den ESC-Leitlinien 2015 Ventrikuläre Arrhythmien und Prävention des plötzlichen Herztodes. <i>Kardiologe</i> , 2017 , 11, 27-43	0.6	8
184	Recent advances in rhythm control for atrial fibrillation. <i>F1000Research</i> , 2017 , 6, 1796	3.6	8
183	ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017 , 38, 2643-2645	9.5	8
182	Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. <i>American Heart Journal</i> , 2010 , 159, 1108-15	4.9	8
181	Effect of sotalol and acute ventricular dilatation on action potential duration and dispersion of repolarization after defibrillation shocks. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 41, 640-8	3.1	8
180	Pauses after burst pacing provoke afterdepolarizations and torsades de pointes in a patient with long QT syndrome. <i>Heart Rhythm</i> , 2004 , 1, 720-3	6.7	8
179	Disturbed lipid and amino acid metabolisms in COVID-19 patients.. <i>Journal of Molecular Medicine</i> , 2022 , 100, 555	5.5	8
178	Mortality Prediction of the CHADS-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
177	The future of continuing medical education: the roles of medical professional societies and the health care industry. <i>European Heart Journal</i> , 2019 , 40, 1720-1727	9.5	8
176	The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. <i>American Journal of Medicine</i> , 2019 , 132, 921-925	2.4	7
175	High-Throughput Analysis of Optical Mapping Data Using ElectroMap. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	7
174	Kommentar zu den Leitlinien der ESC zum Vorhofflimmern. <i>Kardiologe</i> , 2012 , 6, 12-27	0.6	7
173	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Hipertension Y Riesgo Vascular</i> , 2013 , 30, 4-91	0.5	7
172	Ectopic thyroid mass in the heart. <i>Lancet, The</i> , 2012 , 379, 1762	4.0	7

171	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. <i>Europace</i> , 2011 , 13, 1063-76	3.9	7
170	The German Competence Network on Atrial Fibrillation (AFNET). <i>Herz</i> , 2008 , 33, 548-55	2.6	7
169	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016239	6	7
168	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 50.e1-50.e84	1.5	6
167	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 120	2.3	6
166	Digital learning and the future cardiologist. <i>European Heart Journal</i> , 2019 , 40, 499-501	9.5	6
165	Automatic Holter electrocardiogram analysis in ischaemic stroke patients to detect paroxysmal atrial fibrillation: ready to replace physicians?. <i>European Journal of Neurology</i> , 2020 , 27, 1272-1278	6	6
164	Right atrial scar detection after catheter ablation: Comparison of 2D and high spatial resolution 3D-late enhancement magnetic resonance imaging. <i>Academic Radiology</i> , 2011 , 18, 488-94	4.3	6
163	Effect of electrode position on the outcome of cardioversion. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 292-6		6
162	Induction of ventricular fibrillation by T-wave field-shocks in the isolated perfused rabbit heart: Role of nonuniform shock responses. <i>Basic Research in Cardiology</i> , 1997 , 92, 35-44	11.8	6
161	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. <i>Heart</i> , 2020 , 106, 1919-1926	5.1	6
160	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 229-237	4.6	6
159	A tale of two countries: how decentralized organization and long-term investment build resilient healthcare systems. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 201-203	4.6	5
158	Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 69.e1-69.e49	1.5	5
157	To the Editor--Propranolol, a β -adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. <i>Heart Rhythm</i> , 2014 , 11, e1	6.7	5
156	Drugs that interact with cardiac electro-mechanics: old and new targets for treatment. <i>Progress in Biophysics and Molecular Biology</i> , 2008 , 97, 497-512	4.7	5
155	In vivo recording of monophasic action potentials in awake dogs--new applications for experimental electrophysiology. <i>Basic Research in Cardiology</i> , 2001 , 96, 169-74	11.8	5
154	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. <i>Europace</i> , 2020 , 22, 1337-1344	3.9	5

153	Novel Wide-Band Dielectric Imaging System and Occlusion Tool to Guide Cryoballoon-Based Pulmonary Vein Isolation: Feasibility and First Insights. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e009219	6.4	5
152	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1932-1948	15.1	5
151	The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. <i>Europace</i> , 2015 , 17, 1457-66	3.9	4
150	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020 , 318, 67-73	3.2	4
149	Kommentar: Fokus Update der Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des Vorhofflimmerns. <i>Kardiologe</i> , 2013 , 7, 171-180	0.6	4
148	Bleeding risk assessment and management in atrial fibrillation patients. <i>European Heart Journal</i> , 2012 , 33, 147-9	9.5	4
147	Coincidence of paroxysmal supraventricular tachycardia and panic disorder: two case reports. <i>Annals of General Psychiatry</i> , 2010 , 9, 13	3.4	4
146	In vivo recording of monophasic action potentials in awake dogs. <i>Methods</i> , 2003 , 30, 109-14	4.6	4
145	Intracardiac tuberculoma causing "idiopathic" ventricular tachycardia in a patient without detectable heart disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 118	2.7	4
144	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. <i>Circulation</i> , 2022 , 145, 392-409	16.7	4
143	Preclinical testing of drug-induced proarrhythmia: value of transgenic models. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2007 , 5, 289-94	1.9	4
142	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. <i>Cardiovascular Research</i> , 2021 ,	9.9	4
141	Biomarkers Associated With Aortic Valve Calcification: Should We Focus on Sex Specific Processes?. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 604	5.7	4
140	Can biomarkers balance stroke and bleeding risk?. <i>Lancet, The</i> , 2016 , 387, 2266-2268	4.0	4
139	The additive prognostic value of coronary calcium score (CCS) to single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI)-real world data from a single center. <i>Journal of Nuclear Cardiology</i> , 2021 , 28, 2086-2096	2.1	4
138	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021 , 23, 1942-1951	12.3	4
137	Applying the ESC 2016, H FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. <i>ESC Heart Failure</i> , 2021 , 8, 3603-3612	3.7	4
136	MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 58	2.3	3

135	First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heart. <i>Circulation: Heart Failure</i> , 2015 , 8, 79-88	7.6	3
134	Is there a CASTLE-AF on the hill?. <i>European Heart Journal</i> , 2018 , 39, 1324-1325	9.5	3
133	The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy. <i>European Heart Journal</i> , 2018 , 39, 2997-2999	9.5	3
132	Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?. <i>Europace</i> , 2019 , 21, 181-183	3.9	3
131	Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants. <i>Europace</i> , 2014 , 16, 149-50	3.9	3
130	EHRA/HRS/APHS expert consensus on ventricular arrhythmias. <i>Journal of Arrhythmia</i> , 2014 , 30, 327-349	9.5	3
129	Grupo de Trabajo Conjunto sobre cirugía no cardíaca: Evaluación y manejo cardiovascular de la Sociedad Europea de Cardiología (ESC) y la European Society of Anesthesiology (ESA). <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 1052.e1-1052.e43	1.5	3
128	Gene construction, expression and functional testing of an inotropic peptide from the venom of the black scorpion <i>Hottentotta judaicus</i> . <i>Toxicon</i> , 2012 , 60, 1415-27	2.8	3
127	Corrigendum to: Guidelines for the management of atrial fibrillation [European Heart Journal (2010) 31, 2369-2429 and EP-Europace (2010) 12, 1360-1420]. <i>European Heart Journal</i> , 2011 , 32, 1172-1172	9.5	3
126	Atrial fibrillation: Ablation of atrial fibrillation: for whom and how?. <i>Heart</i> , 2010 , 96, 1325-30	5.1	3
125	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2011 , 13, 1058-1058	3.9	3
124	Simultaneous in utero assessment of AV nodal and ventricular electrophysiologic parameters in the fetal sheep heart. <i>Basic Research in Cardiology</i> , 2001 , 96, 251-7	11.8	3
123	Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. <i>Kardiologia Polska</i> , 2013 , 71, 27-118	0.9	3
122	Intermittent Optogenetic Tachypacing of Atrial Engineered Heart Tissue Induces Only Limited Electrical Remodelling. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 77, 291-299	3.1	3
121	Temporal irregularity quantification and mapping of optical action potentials using wave morphology similarity. <i>Progress in Biophysics and Molecular Biology</i> , 2020 , 157, 84-93	4.7	3
120	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heart-lung transplantation in the Eurotransplant region. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 1238-1249	5.8	3
119	Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables. <i>Open Heart</i> , 2020 , 7,	3	3
118	Sex differences in patients with cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 1775-1783	3.7	3

117	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
116	CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1757-1769	6.1	3
115	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006852	5.8	3
114	Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. <i>Europace</i> , 2017 , 19, 921-928	3.9	3
113	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019 , 40, 1728-1738	9.5	3
112	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 591-599	3.7	3
111	Effects of genetic background, sex, and age on murine atrial electrophysiology. <i>Europace</i> , 2021 , 23, 958-969	3.6	3
110	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. <i>Systematic Reviews</i> , 2019 , 8, 221	3	2
109	The National Institute for Health Research (NIHR) Global Health Research Group on Atrial Fibrillation management. <i>European Heart Journal</i> , 2019 , 40, 3005-3007	9.5	2
108	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019 , 21, 690-693	12.3	2
107	The Amplitude-Normalized Area of a Bipolar Electrogram as a Measure of Local Conduction Delay in the Heart. <i>Frontiers in Physiology</i> , 2020 , 11, 465	4.6	2
106	Editor's Choice- Practical challenges regarding in-hospital telemetry monitoring require the development of European practice standards. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 774-776	4.3	2
105	Almanac 2015: atrial fibrillation research in Heart. <i>Heart</i> , 2016 , 102, 573-80	5.1	2
104	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019 , 21, 421-427	3.9	2
103	NOACs in Atrial Fibrillation. <i>European Heart Journal</i> , 2017 , 38, 2382-2385	9.5	2
102	MRI of right atrial function after catheter ablation of atrial flutter. <i>Academic Radiology</i> , 2010 , 17, 856-61	4.3	2
101	Data mining for detecting disturbances in heart rhythm 2008 ,		2
100	Vorhofflimmern - eine Standortbestimmung - Vorkommen, Mechanismen und klinische Präsentation. <i>Klinikerzt</i> , 2008 , 37, 66-70	0	2

99	Mechanism of catecholamine-induced ventricular tachycardias in mice with heart-directed expression of junctin and triadin: Shortening of action potentials and prolonged calcium transients. <i>Heart Rhythm</i> , 2005 , 2, S69	6.7	2
98	Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 973-975	7	2
97	Genetic aspects in acquired long QT syndrome ? a piece in the puzzle. <i>European Heart Journal Supplements</i> , 2001 , 3, K48-K52	1.5	2
96	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013 , 2, 115-9	3.2	2
95	A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. <i>Biomolecules</i> , 2021 , 11,	5.9	2
94	Endovascular extraction of a coronary stent: resolution of a cathlab nightmare. <i>EuroIntervention</i> , 2011 , 7, 1008	3.1	2
93	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020 , 22, 250-258	3.9	2
92	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. <i>Clinical Cardiology</i> , 2020 , 43, 1405-1413	3.3	2
91	Heart failure in adults with congenital heart disease: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 529-537	2.6	2
90	Regulation of basal and norepinephrine-induced cAMP and I in hiPSC-cardiomyocytes: Effects of culture conditions and comparison to adult human atrial cardiomyocytes. <i>Cellular Signalling</i> , 2021 , 82, 109970	4.9	2
89	Mobile health for walking on the tightrope of optimal physical activity to reduce the risk of atrial fibrillation. <i>European Heart Journal</i> , 2021 , 42, 2484-2486	9.5	2
88	Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone. <i>Heart Rhythm</i> , 2021 , 18, 1212-1220	6.7	2
87	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
86	CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
85	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024932	6	2
84	Patient-centred care of patients with ventricular arrhythmias and risk of sudden cardiac death: What do the 2015 European Society of Cardiology guidelines add?. <i>European Journal of Cardiovascular Nursing</i> , 2017 , 16, 558-564	3.3	1
83	26 Digoxin [Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. <i>Heart</i> , 2015 , 101, A14.2-A15	5.1	1
82	Self-palpation for detection of paroxysmal atrial fibrillation: Much noise with little signal. <i>PLoS Medicine</i> , 2020 , 17, e1003098	11.6	1

81	Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?. <i>European Heart Journal</i> , 2018 , 39, 450-452	9.5	1
80	Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry. <i>Value in Health</i> , 2014 , 17, A497 ³⁻³		1
79	Training the next generation of cardiovascular leaders in health policy and economics. <i>European Heart Journal</i> , 2017 , 38, 3332-3335	9.5	1
78	83 Use of feature tracking to assess systemic right ventricles in congenital heart disease patients with both single and dual ventricular circulations. <i>Heart</i> , 2017 , 103, A60.2-A62	5.1	1
77	205 Atrial Arrhythmia Susceptibility in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Heart</i> , 2014 , 100, A112.2-A113	5.1	1
76	Author reply: To PMID 23625942. <i>Europace</i> , 2014 , 16, 151-2	3.9	1
75	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. <i>Europace</i> , 2012 , 14, 277-277	3.9	1
74	Cardiovert!--or better wait a little? Systematic evidence that the initial hours of atrial fibrillation are a "special time". <i>Heart Rhythm</i> , 2005 , 2, 1330-1	6.7	1
73	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery. <i>BMJ Open</i> , 2020 , 10, e042176	3	1
72	Cytokine-Mediated Alterations of Human Cardiac Fibroblast's Secretome. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
71	Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 373-83	3.3	1
70	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. <i>Data in Brief</i> , 2021 , 39, 107451	1.2	1
69	Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart		1
68	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillation-a dedication to Harry Crijns. <i>Europace</i> , 2021 , 23, ii34-ii39	3.9	1
67	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021 , 84, 485-490	2.8	1
66	Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?. <i>Cardiovascular Research</i> , 2021 , 117, 1718-1731	9.9	1
65	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). <i>Europace</i> , 2021 , 23, 1903-1912	3.9	1
64	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021 , 110, 938-958	6.1	1

63	Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211021171	3.3	1
62	Anticoagulation management in adult patients with congenital heart disease: a narrative review.. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 1324-1333	2.6	1
61	Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease-a 10-year, single-center experience.. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 1344-1355	2.6	1
60	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. <i>PLoS Medicine</i> , 2021 , 18, e1003405	11.6	1
59	Study design and rationale of the pAtients pResenTing with cOngenital hearT dIseAse Register (ARTORIA-R). <i>ESC Heart Failure</i> , 2021 ,	3.7	1
58	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome. <i>American Journal of Cardiology</i> , 2021 , 157, 22-32	3	1
57	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery 2020 , 10, e042176		1
56	Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry. <i>Value in Health</i> , 2014 , 17, A473	3.3	0
55	Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence. <i>Europace</i> , 2009 , 11, 842-3	3.9	0
54	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death.. <i>Journal of the American Heart Association</i> , 2022 , e022833	6	0
53	Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels.. <i>Journal of Molecular and Cellular Cardiology</i> , 2022 , 166, 23-35	5.8	0
52	Basic Research Approaches to Evaluate Cardiac Arrhythmia in Heart Failure and Beyond.. <i>Frontiers in Physiology</i> , 2022 , 13, 806366	4.6	0
51	Spirolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-42	1.7	0
50	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022 , 346, 19-26	3.2	0
49	In Patients With Recently Diagnosed Atrial Fibrillation, Think Anticoagulation and Rhythm Control. <i>Circulation</i> , 2021 , 144, 1587-1589	16.7	0
48	Integrated care in stroke survivors: When and how much?. <i>EClinicalMedicine</i> , 2020 , 25, 100489	11.3	0
47	Trusting our cardiology trainees. <i>European Heart Journal</i> , 2020 , 41, 3601-3602	9.5	0
46	Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	0

45	Second look Holter ECG in neurorehabilitation. <i>Neurological Research and Practice</i> , 2019 , 1, 41	3.2	o
44	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. <i>Critical Care</i> , 2021 , 25, 325	10.8	o
43	High resolution optical mapping of cardiac electrophysiology in pre-clinical models.. <i>Scientific Data</i> , 2022 , 9, 135	8.2	o
42	The Atrial Fibrillation Heart Team-guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence.. <i>European Heart Journal</i> , 2022 , 43, 1691-1692	9.5	o
41	44 Diagnostic yield of 7-day holter ecg monitoring for new af and association with comorbidities. outcomes in an all-comer cohort from a large teaching trust. <i>Heart</i> , 2017 , 103, A35-A36	5.1	
40	Education as a vehicle towards quality improvement in the European Society of Cardiology. <i>Cardiovascular Research</i> , 2019 , 115, e80-e81	9.9	
39	Diagnostik und Behandlung von Vorhofflimmern. <i>CME (Berlin, Germany)</i> , 2015 , 12, 49-57	o	
38	168 Atrial arrhythmias and electrical remodelling after endurance training in a mouse model of arrhythmogenic right ventricular cardiomyopathy. <i>Heart</i> , 2015 , 101, A95.2-A96	5.1	
37	Begleitmedikation bei Therapie mit direkten oralen Antikoagulanzen. <i>Kardiologe</i> , 2020 , 14, 29-31	0.6	
36	Innovations in Antiarrhythmic Drug Therapy 2018 , 1076-1083		
35	170 Plakoglobin Deficiency Predisposes to Left Atrial Electrical Remodeling Following Chronic Exposure to Anabolic Steroids. <i>Heart</i> , 2016 , 102, A119-A119	5.1	
34	217 Differences in Blood Biomarker Composition Between Paroxysmal AF and Sinus Rhythm Patients, Without Heart Failure. <i>Heart</i> , 2016 , 102, A143.2-A144	5.1	
33	199 Pitx2c Deficiency May Increase the Antiarrhythmic Properties of Flecainide. <i>Heart</i> , 2014 , 100, A109.2-A110	5.1	
32	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 131.e1-131.e42	1.5	
31	188 Development of a novel software package for high-throughput processing and analysis of cardiac optical mapping data. <i>Heart</i> , 2017 , 103, A128.2-A129	5.1	
30	221 Altered biophysical properties of the voltage-gated sodium channels in mouse atrial and ventricular cardiomyocytes. <i>Heart</i> , 2017 , 103, A143.3-A144	5.1	
29	YIA5 Plakoglobin Deficiency Leads to Increased Biventricular Beta-Catenin Expression in the Murine Heart. <i>Heart</i> , 2015 , 101, A124.1-A124	5.1	
28	YIA3 Regional Action Potential Gradients in the Murine Left Atrium. <i>Heart</i> , 2015 , 101, A123.1-A123	5.1	

27	191 Advancement of Optical Mapping through Automated Algorithms and Second Generation CMOS Detectors to Reveal Murine Atrial Activation Patterns and Regional Variation of Action Potential Duration. <i>Heart</i> , 2014 , 100, A106.1-A106	5.1
26	New Antiarrhythmic Drugs and New Concepts for Old Drugs 2014 , 1111-1119	
25	The European Network for Translational Research in Atrial Fibrillation. <i>Clinical Investigation</i> , 2012 , 2, 1061-1067	
24	Antiarrhythmic drug treatment after cardioversion of atrial fibrillation [Authors' reply]. <i>Lancet, The</i> , 2012 , 380, 1468	4.0
23	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. <i>Europace</i> , 2013 , 15, 460-1	3.9
22	Questionable levels of evidence in new atrial fibrillation guidelines? Reply. <i>Europace</i> , 2013 , 15, 461-2	3.9
21	Cell-based therapy of the failing heart: a need to connect for proper electrical and contractile function. <i>Europace</i> , 2010 , 12, 1520-1	3.9
20	Does omega-3 fatty acid supplementation prevent atrial fibrillation, and if so, which type?. <i>Heart Rhythm</i> , 2011 , 8, 569-70	6.7
19	Moderne Diagnostik und Schlaganfallprävention bei Vorhofflimmern. <i>Aktuelle Neurologie</i> , 2011 , 38, 58-67	
18	A real-time tip manometer for radiofrequency catheter ablation: new toy or useful tool?. <i>Europace</i> , 2011 , 13, 159-60	3.9
17	"Zooming in" to new horizons: conduction abnormalities and other research perspectives in atrial fibrillation. <i>Heart Rhythm</i> , 2009 , 6, 1118-9	6.7
16	Recording Monophasic Action Potentials 2005 , 417-431	
15	Molekulare Mechanismen des plötzlichen Herztods und ihre klinische Bedeutung. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2003 , 14, 168-179	0.8
14	Pharmacology of Sudden Cardiac Death 203-219	
13	Reproducible conversion from wide to narrow complex tachycardia: what is the mechanism?. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 941-3	2.7
12	Mutation in a Family with a Strong History of Sudden Cardiac Death.. <i>Genes</i> , 2022 , 13,	4.2
11	Influence of severe anemia on procedural safety and one-year outcome after left atrial appendage closure: Insights from a very high-risk cohort.. <i>IJC Heart and Vasculature</i> , 2022 , 38, 100946	2.4
10	The heart and brain imaging in lone atrial fibrillation - are we surprised?. <i>Current Pharmaceutical Design</i> , 2015 , 21, 613-21	3.3

9	169 PITX2C deficiency augments the anti-arrhythmic properties of flecainide: results in a mouse model and validation in a human atrium simulation study. <i>Heart</i> , 2015 , 101, A96.1-A96	5.1
8	Clinical Trials on Atrial Fibrillation/Future Perspectives 137-160	
7	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectiveness-Authors' reply. <i>Europace</i> , 2020 , 22, 1602	3.9
6	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021 , 76, 431-439	0.9
5	Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2546-2547	15.1
4	OCEAN Trial Update. <i>American Heart Journal</i> , 2021 ,	4.9
3	Reply to the Editor-From AFFIRM to EAST-Better rhythm control and general AF management explain differences in outcomes. <i>Heart Rhythm</i> , 2021 , 18, 1814	6.7
2	Simultaneous Whole-Chamber Non-contact Mapping of Highest Dominant Frequency Sites During Persistent Atrial Fibrillation: A Prospective Ablation Study.. <i>Frontiers in Physiology</i> , 2022 , 13, 826449	4.6
1	Association of stroke lesion shape with newly detected atrial fibrillation [Results from the MonDAFIS study. <i>European Stroke Journal</i> , 239698732211008	5.6